

## OMA State of Oklahoma Authority SoonerCare Logtorzi<sup>™</sup> (Torinalimab-tozi) Prior Authorization Form

Loqioizi	(Toripanniab-tpzi) Prior A	
Member Name:	Date of Birth:	Member ID#:
Drug Information		
□ Physician billing (HCPCS code:) □ Pharmacy billing (NDC:)		
Dose: Regimen: Start Date (or date of next dose):		
Billing Provider Information		
Provider NPI: Provider Name:		
Provider Phone: Provider Fax:		
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
<ul> <li>a. Will toripalimab-tpzi be</li> <li>b. Will toripalimab-tpzi be</li> <li>3. Is disease previously treat</li> <li>a. Has disease progresse</li> <li>b. Will toripalimab-tpzi be</li> <li>c. Please provide membe</li> </ul>	current, locally advanced NPC? Y used in the first-line setting? Yes used in combination with cisplatir ed recurrent unresectable or meta ed on or following a platinum-conta used as a single agent? Yes	No n and gemcitabine? YesNo astatic NPC? YesNo aining chemotherapy? YesNo No
3. Has member experienced If yes, please specify adverse Prescriber Signature: I certify that the indicated treatme knowledge. Please do not send in the sender s	vidence of progressive disease wh adverse drug reactions related to reactions:	toripalimab-tpzi therapy? YesNo Date: <i>prmation is true and correct to the best of my</i> requested if necessary. Failure to

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

3/5/2024